{"entity":{"id":"orm-5029","kind":"drug","name":"ORM-5029","aka":[],"tldr":"ORM-5029 is a degrader-antibody conjugate from Orum Therapeutics that reached phase 1 for HER2-expressing advanced solid tumours, including HER2-positive breast cancer; development has stopped.","summary":"ORM-5029 is a degrader-antibody conjugate from Orum Therapeutics. A HER2-targeted antibody carrying a GSPT1-degrading payload into cancer cells. Its furthest stage is phase 1, for HER2-expressing advanced solid tumours, including HER2-positive breast cancer. ClinicalTrials.gov registers it in one study linked below. Orum discontinued clinical development of ORM-5029 (company release of 28 April 2025). The phase 1 NCT05511844 is TERMINATED ('Sponsor Decision'). Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Orum Therapeutics: 1stoncology.com","url":"https://www.1stoncology.com/blog/?p=102707"},{"label":"Orum Therapeutics: clinicaltrials.gov","url":"https://clinicaltrials.gov/study/NCT05511844"},{"label":"ClinicalTrials.gov: trials of ORM-5029","url":"https://clinicaltrials.gov/search?intr=ORM-5029"}],"tags":["pipeline","ctgov-ingest","discontinued"],"related":[],"cancers":["breast-her2-positive"],"sections":[],"technologies":[],"targets":["her2"],"drugs":[],"companies":["orum-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct05511844"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"ORM-5029","modality":"Degrader-antibody conjugate","mechanism":"A HER2-targeted antibody carrying a GSPT1-degrading payload into cancer cells.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/orm-5029/","neighbours":{"cancer":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"}],"target":[{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"}],"company":[{"id":"orum-therapeutics","kind":"company","name":"Orum Therapeutics","route":"/companies/orum-therapeutics/"}],"trial":[{"id":"nct05511844","kind":"trial","name":"Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors","route":"/trials/nct05511844/"}]}}